Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on the Revision of EU GMP Annex 11 on Computerised Systems

On 16 November 2022, the European Medicines Agency EMA published a concept paper on the planned revision of Annex 11 "Computerised Systems". The reason: The existing document of the EU GMP Guideline dates back to 2011 and no longer corresponds to the state of the art in various areas or does not consider increasingly important new technologies for the GMP field, according to the EMA.

In short:

A new focus is to be on data integrity, in particular the requirements for "data in motion", and data in archives or in backup, the so called "data at rest". The requirements for providers of e.g., cloud services are also to go into more detail and the meaning of "validation and qualification of the systems" is to be clarified in greater depth. This also applies to the term "commercial off-the-shelf products". References to ICH Q9 and thus to quality risk management will also be added.

In addition to these classic topics, developments in the field of artificial intelligence will be included in the future. There are currently no regulatory guidelines or expectations for AI (artificial intelligence) or ML (machine learning). The main focus here should be on the relevance, appropriateness and integrity of the data with which these models are tested and, on the results (metrics) of such tests.

Of interest is a reference (33.) to the FDA's draft document "Computer Software Assurance for Production and Quality System Software", which was recently published. This important US document is to be reviewed for possible regulatory relevance to Annex 11.

The timeline for a new Annex 11:
The consultation period ends on 16 January 2023, with a draft document to be released for consultation in December 2024. Finalisation of the document is planned for 2026.


Source:

EMA: Concept paper on EU Annex 11 on Computerised Systems

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
What are the General Requirements for Standard Documents?

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
EDQM: Revised Guidance on Sister File Applications

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic has revised its guidance document “Mobile technologies” and added two new entries to the related questions and answers. The update follows an increasing number of queries regarding the details and placement of URLs, the positioning of QR codes and their captions.
Read more
EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA reported that Scholar Rock Netherlands withdrew its application for Isembyld after evaluation had progressed through the final round of questions. EMA’s provisional view was that the medicine could not be authorised because the applicant had not provided confirmation that the manufacturing site complied with EU GMP requirements.

Read more
France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

The French medicines agency ANSM has published an update on its “Longue vie aux médicaments” pilot project aimed at extending the shelf life of medicines. Fourteen pharmaceutical companies responded to the call for applications. The project covers a total of 73 medicines, including commonly used products containing paracetamol, levothyroxine, melatonin or lithium.
Read more
Previous
Next